CEUFAST COURSE

Diabetes Medications

Contact Hour(s): 3 Contact hours, including 3 Advanced Pharmacology HoursAuthor:Dana Bartlett, RN, BSN, MA, MA, CSPIThis peer-reviewed course is applicable for the following professions:Advanced Practice Registered Nurse (APRN), Certifie...

Course Summary

Contact Hour(s): 

3 Contact hours, including 3 Advanced Pharmacology Hours

Author:

Dana Bartlett, RN, BSN, MA, MA, CSPI

This peer-reviewed course is applicable for the following professions:

Advanced Practice Registered Nurse (APRN), Certified Nurse Midwife, Certified Nurse Practitioner, Certified Registered Nurse Anesthetist (CRNA), Certified Registered Nurse Practitioner, Clinical Nurse Specialist (CNS), Dietetic Technicians, Registered (DTR), Dietitian/Nutritionist (RDN), Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Midwife (MW), Nursing Student, Registered Nurse (RN), Registered Nurse Practitioner

Accreditations: 

The American Nurses Credentialing Center (ANCC)

State Approvals:

Alabama Provider #ABNP1485; California BRN Provider #CEP # 13509; Kentucky Board of Nursing Provider #7-0085; Florida Board of Nursing Provider 50-353

Course Description:

This course discusses the issues/topics of insulin, insulin administration, other injectable diabetes medications, and commonly used oral diabetes medications.

Course Outcome:

≥ 92% of participants will know how to administer diabetes medications safely and effectively.

Objectives:

After completing this continuing education course, the participant will be able to:

  1. Describe the mechanism of action of diabetes medications.
  2. Identify the mechanism of action of insulin.
  3. List the significant adverse effects of each medication.
  4. Explain the important considerations of administration of insulin.
  5. Indicate the precautions and US Boxed warnings for diabetes medications.
  6. Compare and contrast the indication for use for each medication.

Disclosures:

CEUFast Inc. and the course planning team for this educational activity do not have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.